Abstract Number: 1465 • ACR Convergence 2020
The Impact of the Combined Vaccination Scheme Against Streptococcus Pneumoniae on the Incidence of Related Infections in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARD: Data from BIOBADASER 3.0
Background/Purpose: Respiratory infections are among the leading causes of hospitalization in rheumatoid arthritis (RA) and Streptococcus Pneumoniae (SP) is one of the most frequent pathogens…Abstract Number: 1547 • ACR Convergence 2020
Role of Artificial Intelligence in Assessment of Peripheral Joint MRI in Inflammatory Arthritis: A Systematic Review and Meta-analysis
Background/Purpose: To summarize the feasibility, reliability, and validity of computer-aided quantification of joint destruction and synovitis on MRI using artificial intelligence (AI) based methods in…Abstract Number: 1609 • ACR Convergence 2020
The Accuracy of Administrative Health Data for Identifying Patients with Rheumatoid Arthritis: A Validation Study Using Medical Records in Western Australia
Background/Purpose: The use of large administrative health datasets is increasingly important in Rheumatology for disease trends and outcome research. We established the West Australian Rheumatic…Abstract Number: 1725 • ACR Convergence 2020
An Investigation of the Relationship Between Patient Reported Outcomes and Biomarkers in a Community Rheumatology Practice
Background/Purpose: Disease presentation and progression in rheumatoid arthritis (RA) is highly heterogeneous and requires careful consideration of outcome measurements to be used for individual patients.…Abstract Number: 1742 • ACR Convergence 2020
Patients’ and Rheumatologists’ Perceptions on Preventive Intervention in Rheumatoid Arthritis and Axial Spondyloarthritis
Background/Purpose: Persons at risk of developing rheumatoid arthritis (RA) may benefit from lifestyle1 or pharmacological2 interventions aimed at primary prevention. Although less studied, the same…Abstract Number: 1759 • ACR Convergence 2020
Rheumatoid Arthritis Affects the Ossicular Joints: A Human Otopathologic Study
Background/Purpose: Inflammation of synovial joints in small and large extremities is commonly seen in Rheumatoid arthritis (RA). To date little is known about how this disease…Abstract Number: 1963 • ACR Convergence 2020
Variation in Quality of Care Among Patient Sociodemographic Groups in RISE Practices
Background/Purpose: Previous studies have shown that sociodemographic factors are associated with quality of care. Using the Rheumatology Informatics System for Effectiveness (RISE) registry, we assessed…Abstract Number: 2002 • ACR Convergence 2020
Incidence and Risk Factors for Herpes Zoster in Rheumatoid Arthritis Patients Receiving Upadacitinib
Background/Purpose: Upadacitinib (UPA) is an oral JAK inhibitor approved for the treatment of rheumatoid arthritis (RA). The background rate of herpes zoster (HZ) in patients…Abstract Number: PP09 • ACR Convergence 2020
An Integrative Approach to Managing Rheumatoid Arthritis (RA): Healing the Body, Mind & Spirit
Background/Purpose: Diagnosed with RA in 2012, rheumatologists prescribed methotrexate or a biologic. As I was profoundly impacted by my mom’s 30-year battle with RA, I…Abstract Number: 0017 • ACR Convergence 2020
Impact of COVID19 on Missed/Cancelled Rheumatology Office Visits and Parenteral Immunosuppressive Medications
Background/Purpose: The global COVID19 pandemic has had a major impact on healthcare. The effect on rheumatology patients and providers is unclear, as is the role…Abstract Number: 0072 • ACR Convergence 2020
Characterizing Heterogeneity of Synovial Macrophages in Rheumatoid Arthritis Patients
Background/Purpose: Macrophages in the synovial lining of the joint are critical players in the pathogenesis of rheumatoid arthritis (RA). While they are potent producers of…Abstract Number: 0142 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs: Results from the FINCH 2 Study
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor which is currently being investigated as an agent to treat rheumatoid arthritis (RA).…Abstract Number: 0180 • ACR Convergence 2020
Clinicopathological Characteristics of Lymphoproliferative Disorders in 232 Patients with Rheumatoid Arthritis in Japan
Background/Purpose: Lymphoproliferative disorders (LPDs) in patients with rheumatoid arthritis (RA) are one of potentially life-threatening complications. However, the diagnosis of LPDs is complicated by the…Abstract Number: 0197 • ACR Convergence 2020
The Clinical and Laboratory Features of Seronegative Rheumatoid Arthritis with and Without Malignancy
Background/Purpose: Patients with elderly onset rheumatoid arthritis(RA) have been reported to be less positive for RF(rheumatoid factor) and ACPA(anti-cyclic citrullinated peptide antibody), and have a…Abstract Number: 0213 • ACR Convergence 2020
Sustainability of Response to Upadacitinib as Monotherapy or in Combination Among Patients with Rheumatoid Arthritis and Prior Inadequate Response to Conventional Synthetic DMARDs
Background/Purpose: To assess long-term sustainability of responses to upadacitinib (UPA), a JAK inhibitor, with or without background csDMARD(s) in patients (pts) with rheumatoid arthritis (RA).Methods:…
- « Previous Page
- 1
- …
- 159
- 160
- 161
- 162
- 163
- …
- 188
- Next Page »